Advertisement

Cancer Causes & Control

, Volume 27, Issue 5, pp 679–693 | Cite as

Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry

  • Zhiguo Zhao
  • Wanqing Wen
  • Kyriaki Michailidou
  • Manjeet K. Bolla
  • Qin Wang
  • Ben Zhang
  • Jirong Long
  • Xiao-Ou Shu
  • Marjanka K. Schmidt
  • Roger L. Milne
  • Montserrat García-Closas
  • Jenny Chang-Claude
  • Sara Lindstrom
  • Stig E. Bojesen
  • Habibul Ahsan
  • Kristiina Aittomäki
  • Irene L. Andrulis
  • Hoda Anton-Culver
  • Volker Arndt
  • Matthias W. Beckmann
  • Alicia Beeghly-Fadiel
  • Javier Benitez
  • Carl Blomqvist
  • Natalia V. Bogdanova
  • Anne-Lise Børresen-Dale
  • Judith Brand
  • Hiltrud Brauch
  • Hermann Brenner
  • Barbara Burwinkel
  • Qiuyin Cai
  • Graham Casey
  • Georgia Chenevix-Trench
  • Fergus J. Couch
  • Angela Cox
  • Simon S. Cross
  • Kamila Czene
  • Thilo Dörk
  • Martine Dumont
  • Peter A. Fasching
  • Jonine Figueroa
  • Dieter Flesch-Janys
  • Olivia Fletcher
  • Henrik Flyger
  • Florentia Fostira
  • Marilie Gammon
  • Graham G. Giles
  • Pascal Guénel
  • Christopher A. Haiman
  • Ute Hamann
  • Patricia Harrington
  • Mikael Hartman
  • Maartje J. Hooning
  • John L. Hopper
  • Anna Jakubowska
  • Farzana Jasmine
  • Esther M. John
  • Nichola Johnson
  • Maria Kabisch
  • Sofia Khan
  • Muhammad Kibriya
  • Julia A. Knight
  • Veli-Matti Kosma
  • Mieke Kriege
  • Vessela Kristensen
  • Loic Le Marchand
  • Eunjung Lee
  • Jingmei Li
  • Annika Lindblom
  • Artitaya Lophatananon
  • Robert Luben
  • Jan Lubinski
  • Kathleen E. Malone
  • Arto Mannermaa
  • Siranoush Manoukian
  • Sara Margolin
  • Frederik Marme
  • Catriona McLean
  • Hanne Meijers-Heijboer
  • Alfons Meindl
  • Hui Miao
  • Kenneth Muir
  • Susan L. Neuhausen
  • Heli Nevanlinna
  • Patrick Neven
  • Janet E. Olson
  • Barbara Perkins
  • Paolo Peterlongo
  • Kelly-Anne Phillips
  • Katri Pylkäs
  • Anja Rudolph
  • Regina Santella
  • Elinor J. Sawyer
  • Rita K. Schmutzler
  • Minouk Schoemaker
  • Mitul Shah
  • Martha Shrubsole
  • Melissa C. Southey
  • Anthony J. Swerdlow
  • Amanda E. Toland
  • Ian Tomlinson
  • Diana Torres
  • Thérèse Truong
  • Giske Ursin
  • Rob B. Van Der Luijt
  • Senno Verhoef
  • Shan Wang-Gohrke
  • Alice S. Whittemore
  • Robert Winqvist
  • M. Pilar Zamora
  • Hui Zhao
  • Alison M. Dunning
  • Jacques Simard
  • Per Hall
  • Peter Kraft
  • Paul Pharoah
  • David Hunter
  • Douglas F. Easton
  • Wei ZhengEmail author
Original paper

Abstract

Purpose

Type 2 diabetes (T2D) has been reported to be associated with an elevated risk of breast cancer. It is unclear, however, whether this association is due to shared genetic factors.

Methods

We constructed a genetic risk score (GRS) using risk variants from 33 known independent T2D susceptibility loci and evaluated its relation to breast cancer risk using the data from two consortia, including 62,328 breast cancer patients and 83,817 controls of European ancestry. Unconditional logistic regression models were used to derive adjusted odds ratios (ORs) and 95 % confidence intervals (CIs) to measure the association of breast cancer risk with T2D GRS or T2D-associated genetic risk variants. Meta-analyses were conducted to obtain summary ORs across all studies.

Results

The T2D GRS was not found to be associated with breast cancer risk, overall, by menopausal status, or for estrogen receptor positive or negative breast cancer. Three T2D associated risk variants were individually associated with breast cancer risk after adjustment for multiple comparisons using the Bonferroni method (at p < 0.001), rs9939609 (FTO) (OR 0.94, 95 % CI = 0.92–0.95, p = 4.13E−13), rs7903146 (TCF7L2) (OR 1.04, 95 % CI = 1.02–1.06, p = 1.26E−05), and rs8042680 (PRC1) (OR 0.97, 95 % CI = 0.95–0.99, p = 8.05E−04).

Conclusions

We have shown that several genetic risk variants were associated with the risk of both T2D and breast cancer. However, overall genetic susceptibility to T2D may not be related to breast cancer risk.

Keywords

Type 2 diabetes Genetic susceptibility GWAS Breast cancer Epidemiology 

Notes

Acknowledgments

We thank all the individuals who took part in these studies and all the researchers, study staff, clinicians and other healthcare providers, technicians, and administrative staff who have enabled this work to be carried out. In particular, we thank: Andrew Berchuck (OCAC); Rosalind A. Eeles, Ali Amin Al Olama, Zsofia Kote-Jarai, Sara Benlloch (PRACTICAL); Antonis Antoniou, Lesley McGuffog, Ken Offit (CIMBA); Joe Dennis, Andrew Lee, Ed Dicks, Craig Luccarini, and the staff of the Centre for Genetic Epidemiology Laboratory; Javier Benitez, Anna Gonzalez-Neira, and the staff of the CNIO genotyping unit; Jacques Simard, Daniel C. Tessier, Francois Bacot, Daniel Vincent, Sylvie LaBoissière, Frederic Robidoux, and the staff of the McGill University and Génome Québec Innovation Centre; Sune F. Nielsen, Borge G. Nordestgaard, and the staff of the Copenhagen DNA laboratory; and Julie M. Cunningham, Sharon A. Windebank, Christopher A. Hilker, Jeffrey Meyer, and the staff of Mayo Clinic Genotyping Core Facility; Maggie Angelakos, Judi Maskiell, Gillian Dite (ABCFS), Ellen van der Schoot, Femake Atsma (Sanquin Bloodbank); Emiel Rutgers, Senno Verhoef, Frans Hogervorst, the Thai Ministry of Public Health (MOPH); Dr. Prat Boonyawongviroj (former Permanent Secretary of MOPH); Dr. Pornthep Siriwanarungsan (Department Director-General of Disease Control); Michael Schrauder, Matthias Rübner, Sonja Oeser, Silke Landrith, Eileen Williams, Elaine Ryder-Mills, Kara Sargus, Niall McInerney, Gabrielle Colleran, Andrew Rowan, Angela Jones, Christof Sohn, Andeas Schneeweiß, and Peter Bugert (the Danish Breast Cancer Group); Núria Álvarez; the CTS Steering Committee (including Leslie Bernstein, James Lacey, Sophia Wang, Huiyan Ma, Yani Lu, and Jessica Clague DeHart at the Beckman Research Institute of the City of Hope; Dennis Deapen, Rich Pinder, Eunjung Lee and Fred Schumacher at the University of Southern California; Pam Horn-Ross, Peggy Reynolds, and David Nelson at the Cancer Prevention Institute of California; and Hannah Park at the University of California Irvine); Hartwig Ziegler; Sonja Wolf; Volker Hermann; the GENICA network [Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Germany; (HB, Wing-Yee Lo, Christina Justenhoven), Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany (Yon-Dschun Ko, Christian Baisch), Institute of Pathology, University of Bonn, Germany (Hans-Peter Fischer), Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ) Heidelberg, Germany (UH), Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Germany (Thomas Brüning, Beate Pesch, Sylvia Rabstein, Anne Lotz), Institute of Occupational Medicine and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Germany (Volker Harth)]; Tuomas Heikkinen; Irja Erkkilä; Kirsimari Aaltonen; Karl von Smitten; Natalia Antonenkova; Peter Hillemanns; Hans Christiansen; Eija Myöhänen; Helena Kemiläinen; Heather Thorne; Eveline Niedermayr; the AOCS Management Group (D Bowtell, G Chenevix-Trench, A deFazio, D Gertig, A Green, P Webb); the ACS Management Group (A Green, P Parsons, N Hayward, P Webb, D Whiteman); the LAABC data collection team, especially Annie Fung and June Yashiki; Gilian Peuteman; Dominiek Smeets; Thomas Van Brussel; Kathleen Corthouts; Nadia Obi; Judith Heinz; Sabine Behrens; Ursula Eilber; Muhabbet Celik; Til Olchers; the Mayo Clinic Breast Cancer Patient Registry; Martine Tranchant; Marie-France Valois; Annie Turgeon; Lea Heguy; Phuah Sze Yee; Peter Kang; Kang In Nee; Shivaani Mariapun; Yoon Sook-Yee; Daphne Lee; Teh Yew Ching; Nur Aishah Mohd Taib; Meeri Otsukka; Kari Mononen; Teresa Selander; Nayana Weerasooriya; OFBCR staff: E Krol-Warmerdam, J Molenaar, J Blom; Louise Brinton; Neonila Szeszenia-Dabrowska; Beata Peplonska; Witold Zatonski; Pei Chao; Michael Stagner; Petra Bos; Jannet Blom; Ellen Crepin; Anja Nieuwlaat; Annette Heemskerk; the Erasmus MC Family Cancer Clinic; Sue Higham; Simon Cross; Helen Cramp; Dan Connley; Sabapathy Balasubramanian; Ian Brock; the Eastern Cancer Registration and Information Centre; the SEARCH and EPIC teams; Michael Kerin, Nicola Miller, Niall McInerney, Gabrielle Colleran (BIGGS), and Pierre Kerbrat; Patrick Arveux; Romuald Le Scodan; Yves Raoul; Pierre Laurent-Puig; Claire Mulot (CECILE), Hartwig Ziegler, Sonja Wolf, Volker Hermann, Christa Stegmaier and Katja Butterbach (ESTHER), Taru A. Muranen (HEBCS), Natalia Antonenkova, Peter Hillemanns, Hans Christiansen and Johann H. Karstens (HMBCS), Gilian Peuteman, Dominiek Smeets, Thomas Van Brussel and Kathleen Corthouts (LMBC), Petra Seibold, Judith Heinz, Nadia Obi, Alina Vrieling, Sabine Behrens, Ursula Eilber, Muhabbet Celik, Til Olchers and Stefan Nickels (MARIE). MBCSG wish to thank Paolo Radice, Bernard Peissel, and Daniela Zaffaroni of the Fondazione IRCCS Istituto Nazionale dei Tumori (INT); Bernardo Bonanni, Monica Barile, and Irene Feroce of the Istituto Europeo di Oncologia (IEO) and Loris Bernard and the personnel of the Cogentech Cancer Genetic Test Laboratory. Cancer Council Victoria acknowledges the Traditional Owners of the land and waters throughout Victoria and pays respect to them, their culture and their Elders past, present, and future. We would like to thank Martine Tranchant (Cancer Genomics Laboratory, CHU de Québec Research Center), Marie-France Valois, Annie Turgeon, and Lea Heguy (McGill University Health Center, Royal Victoria Hospital; McGill University) for DNA extraction, sample management, and skillful technical assistance. J.S. is Chairholder of the Canada Research Chair in Oncogenetics. OBCS thanks Arja Jukkola-Vuorinen, Mervi Grip, Saila Kauppila, Kari Mononen, and Meeri Otsukka for data collection and sample preparation. Craig Luccarini; Don Conroy; Caroline Baynes; Kimberley Chua; the Ohio State University Human Genetics Sample Bank; and Robert Pilarski. Data on SCCS cancer cases used in this publication were provided by the: Alabama Statewide Cancer Registry; Kentucky Cancer Registry, Lexington, KY; Tennessee Department of Health, Office of Cancer Surveillance; Florida Cancer Data System; North Carolina Central Cancer Registry, North Carolina Division of Public Health; Georgia Comprehensive Cancer Registry; Louisiana Tumor Registry; Mississippi Cancer Registry; South Carolina Central Cancer Registry; Virginia Department of Health, Virginia Cancer Registry; and Arkansas Department of Health, Cancer Registry. DFBBCS thank Muriel Adank for selecting the samples and Margreet Ausems, Christi van Asperen, Senno Verhoef, and Rogier van Oldenburg for providing samples from their Clinical Genetic centers. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera, and Marjolein Peters for their help in creating the GWAS database, and Karol Estrada and Maksim V. Struchalin for their support in creation and analysis of imputed data. The authors are grateful to the study participants, the staff from the Rotterdam Study, and the participating general practitioners and pharmacists.

Financial Support

The work conducted for this project at the Vanderbilt Epidemiology Center is supported in part by NIH Grant R37CA070867 and endowment funds for the Ingram Professorship and Anne Potter Wilson Chair in Medicine. BCAC is funded by Cancer Research UK (C1287/A10118, C1287/A12014) and by the European Community’s Seventh Framework Programme under Grant agreement no 223175 (HEALTH-F2–2009-223175) (COGS). Meetings of the BCAC have been funded by the European Union COST programme (BM0606). Genotyping of the iCOGS array was funded by the European Union (HEALTH-F2-2009-223175), Cancer Research UK (C8197/A16565 and C1287/A10710), the Canadian Institutes of Health Research for the ‘CIHR Team in Familial Risks of Breast Cancer’ program and the Ministry of Economic Development, Innovation and Export Trade of Quebec (PSR-SIIRI-701). Additional support for the iCOGS infrastructure was provided by the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065, and 1U19 CA148112—the GAME-ON initiative), the Department of Defense (W81XWH-10-1-0341), Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. The Australia, California, and Ontario sites of the Breast Cancer Family Registry were supported by Grant UM1 CA164920 from the National Cancer Institute (USA). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR. The ABCFS (Australia site of the BCFR) was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia) and the Victorian Breast Cancer Research Consortium. John L. Hopper is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow and M.C.S. is a NHMRC Senior Research Fellow. Work at the OFBCR (Ontario site of the BCFR) was also supported by the Canadian Institutes of Health Research ‘CIHR Team in Familial Risks of Breast Cancer’ program. The ABCS study was supported by the Dutch Cancer Society [Grants NKI 2007-3839; 2009 4363] and BBMRI-NL, which is a Research Infrastructure financed by the Dutch government (NWO 184.021.007). The work of the BBCC was partly funded by ELAN-Fond of the University Hospital of Erlangen. The BBCS is funded by Cancer Research UK and Breakthrough Breast Cancer and acknowledges NHS funding to the NIHR Biomedical Research Centre, and the National Cancer Research Network (NCRN). Elinor J. Sawyer is supported by NIHR Comprehensive Biomedical Research Centre, Guy’s & St. Thomas’ NHS Foundation Trust in partnership with King’s College London, UK. Core funding to the Wellcome Trust Centre for Human Genetics was provided by the Wellcome Trust (090532/Z/09/Z). Ian Tomlinson is supported by the Oxford Biomedical Research Centre. The BSUCH study was supported by the Dietmar-Hopp Foundation, the Helmholtz Society, and the German Cancer Research Center (DKFZ). The CECILE study was funded by Fondation de France, Institut National du Cancer (INCa), Ligue Nationale contre le Cancer, Agence Nationale de Sécurité Sanitaire (ANSES), and Agence Nationale de la Recherche (ANR). The CGPS was supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council, and Herlev Hospital. The CNIO-BCS was supported by the Genome Spain Foundation, the Red Temática de Investigación Cooperativa en Cáncer, and grants from the Asociación Española Contra el Cáncer and the Fondo de Investigación Sanitario (PI11/00923 and PI081120). The Human Genotyping-CEGEN Unit, CNIO is supported by the Instituto de Salud Carlos III. The CTS was initially supported by the California Breast Cancer Act of 1993 and the California Breast Cancer Research Fund (contract 97-10500) and is currently funded through the National Institutes of Health (R01 CA77398). Collection of cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885. HAC receives support from the Lon V Smith Foundation (LVS39420). The ESTHER study was supported by a grant from the Baden Württemberg Ministry of Science, Research and Arts. Additional cases were recruited in the context of the VERDI study, which was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe). The GENICA was funded by the Federal Ministry of Education and Research (BMBF) Germany Grants 01KW9975/5, 01KW9976/8, 01KW9977/0, and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus Bonn, Germany. The HEBCS was supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society, the Nordic Cancer Union, and the Sigrid Juselius Foundation. The HMBCS was supported by the Rudolf Bartling Foundation. Financial support for KARBAC was provided through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institute, the Stockholm Cancer Foundation, and the Swedish Cancer Society. The KBCP was financially supported by the special Government Funding (EVO) of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, the Academy of Finland, and by the strategic funding of the University of Eastern Finland. kConFab is supported by grants from the National Breast Cancer Foundation, the NHMRC, the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. The kConFab Clinical Follow Up Study was funded by the NHMRC (145684, 288704, 454508). Kelly-Anne Phillips is a National Breast Cancer Foundation Fellow (Australia). Financial support for the AOCS was provided by the United States Army Medical Research and Materiel Command (DAMD17-01-1-0729), the Cancer Council of Tasmania and Cancer Foundation of Western Australia, and the NHMRC (199600). Georgia Chenevix-Trench and P.W. are supported by the NHMRC. LMBC is supported by the ‘Stichting tegen Kanker’ (232-2008 and 196-2010). Diether Lambrechts is supported by the FWO and the KULPFV/10/016-SymBioSysII and by a ERC consolidator grant. The MARIE study was supported by the Deutsche Krebshilfe e.V. [70-2892-BR I, 106332, 108253, 108419], the Hamburg Cancer Society, the German Cancer Research Center, and the Federal Ministry of Education and Research (BMBF) Germany [01KH0402]. MBCSG is supported by grants from the Italian Association for Cancer Research (AIRC) and by funds from the Italian citizens who allocated a 5/1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects ‘5 × 1,000’). The MCBCS was supported by the NIH Grants (CA122340, CA128978) and a Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), the Breast Cancer Research Foundation, and a generous gift from the David F. and Margaret T. Grohne Family Foundation and the Ting Tsung and Wei Fong Chao Foundation. MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC Grants 209057, 251553, and 504711 and by infrastructure provided by Cancer Council Victoria. The MEC was supported by NIH Grants CA63464, CA54281, CA098758, and CA132839. The work of MTLGEBCS was supported by the Quebec Breast Cancer Foundation, the Canadian Institutes of Health Research for the ‘CIHR Team in Familial Risks of Breast Cancer’ program—Grant No CRN-87521 and the Ministry of Economic Development, Innovation and Export Trade—Grant No PSR-SIIRI-701. The NBCS was supported by grants from the Norwegian Research council (155218/V40, 175240/S10 to A.L.B.D., FUGE-NFR 181600/V11 to V.N.K. and a Swizz Bridge Award to A.L.B.D.). The NBHS was supported by NIH Grant R01CA100374. Biological sample preparation was conducted the Survey and Biospecimen Shared Resource, which is supported by P30 CA68485. OBCS was supported by the Academy of Finland (Grant Number 250083, 122715 and Center of Excellence Grant Number 251314), the Finnish Cancer Foundation, the Sigrid Juselius Foundation, the University of Oulu, the University of Oulu Support Foundation and the special Governmental EVO funds for Oulu University Hospital-based research activities. This OFBCR was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR. The ORIGO study was supported by the Dutch Cancer Society (RUL 1997-1505) and the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL CP16). The PBCS was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. The pKARMA study was supported by Märit and Hans Rausings Initiative Against Breast Cancer. The RBCS was funded by the Dutch Cancer Society (DDHK 2004-3124, DDHK 2009-4318). The SASBAC was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the US National Institute of Health (NIH), and the Susan G. Komen Breast Cancer Foundation. KC was financed by the Swedish Cancer Society (5128-B07-01PAF). The SBCS was supported by Yorkshire Cancer Research S305PA, S299, and S295. SEARCH is funded by a programme grant from Cancer Research UK (C490/A10124) and supported by the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge. SKKDKFZS is supported by the DKFZ. The SZBCS was supported by Grant PBZ_KBN_122/P05/2004. The TNBCC was supported by: a Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a grant from the Breast Cancer Research Foundation, a generous gift from the David F. and Margaret T. Grohne Family Foundation and the Ting Tsung and Wei Fong Chao Foundation, the Stefanie Spielman Breast Cancer fund and the OSU Comprehensive Cancer Center, DBBR (a CCSG Share Resource by National Institutes of Health Grant P30 CA016056), the Hellenic Cooperative Oncology Group research Grant (HR R_BG/04) and the Greek General Secretary for Research and Technology (GSRT) Program, Research Excellence II, the European Union (European Social Fund—ESF), and Greek national funds through the Operational Program ‘Education and Lifelong Learning’ of the National Strategic Reference Framework (NSRF)—ARISTEIA. The UKBGS is funded by Breakthrough Breast Cancer and the Institute of Cancer Research (ICR). ICR acknowledges NHS funding to the NIHR Biomedical Research Centre. The DFBBCS GWAS was funded by the Netherlands Organisation for Scientific Research (NWO) as part of a ZonMw/VIDI Grant number 91756341. The generation and management of GWAS genotype data for the Rotterdam Study (control samples) are supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012). This study is funded by the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) project nr. 050-060-810.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

10552_2016_741_MOESM1_ESM.docx (226 kb)
Supplementary material 1 (DOCX 225 kb)

References

  1. 1.
    Federation ID (2013) IDF diabetes atlas, 6th edn. International Diabetes Federation, BrusselsGoogle Scholar
  2. 2.
    Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Med 15(7):539–553. doi: 10.1002/(SICI)1096-9136(199807)15:7<539:AID-DIA668>3.0.CO;2-S CrossRefPubMedGoogle Scholar
  3. 3.
    Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29. doi: 10.3322/caac.21208 CrossRefPubMedGoogle Scholar
  4. 4.
    Talamini R, Franceschi S, Favero A, Negri E, Parazzini F, La Vecchia C (1997) Selected medical conditions and risk of breast cancer. Br J Cancer 75(11):1699–1703CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Weiderpass E, Gridley G, Persson I, Nyren O, Ekbom A, Adami HO (1997) Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer J Int du cancer 71(3):360–363CrossRefGoogle Scholar
  6. 6.
    Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, Borch-Johnsen K, Olsen JH (1997) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89(18):1360–1365CrossRefPubMedGoogle Scholar
  7. 7.
    Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA, Manson JE, Nurses’ Health S (2003) Type 2 diabetes and subsequent incidence of breast cancer in the Nurses’ Health Study. Diabetes Care 26(6):1752–1758CrossRefPubMedGoogle Scholar
  8. 8.
    Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE (2006) Diabetes mellitus and breast cancer: a retrospective population-based cohort study. Breast Cancer Res Treat 98(3):349–356. doi: 10.1007/s10549-006-9172-5 CrossRefPubMedGoogle Scholar
  9. 9.
    Xue F, Michels KB (2007) Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 86(3):s823–s835PubMedGoogle Scholar
  10. 10.
    Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer J Int du Cancer 121(4):856–862. doi: 10.1002/ijc.22717 CrossRefGoogle Scholar
  11. 11.
    Hardefeldt PJ, Edirimanne S, Eslick GD (2012) Diabetes increases the risk of breast cancer: a meta-analysis. Endocr Relat Cancer 19(6):793–803. doi: 10.1530/ERC-12-0242 CrossRefPubMedGoogle Scholar
  12. 12.
    Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K, Fairley LL, Boniol M, Zheng T, Zhang Y, Pasterk M, Smans M, Curado MP, Mullie P, Gandini S, Bota M, Bolli GB, Rosenstock J, Autier P (2012) Diabetes and breast cancer risk: a meta-analysis. Br J Cancer 107(9):1608–1617. doi: 10.1038/bjc.2012.414 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D (2010) Diabetes and cancer: a consensus report. CA Cancer J Clin 60(4):207–221. doi: 10.3322/caac.20078 CrossRefPubMedGoogle Scholar
  14. 14.
    Yang G, Lu G, Jin F, Dai Q, Best R, Shu XO, Chen JR, Pan XY, Shrubsole M, Zheng W (2001) Population-based, case-control study of blood C-peptide level and breast cancer risk. Cancer Epidemiol Biomarkers Prev 10(11):1207–1211PubMedGoogle Scholar
  15. 15.
    Endogenous H, Breast Cancer Collaborative G, Key TJ, Appleby PN, Reeves GK, Roddam AW (2010) Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 11(6):530–542. doi: 10.1016/S1470-2045(10)70095-4 CrossRefGoogle Scholar
  16. 16.
    Pierce BL, Austin MA, Ahsan H (2011) Association study of type 2 diabetes genetic susceptibility variants and risk of pancreatic cancer: an analysis of PanScan-I data. Cancer Causes Control CCC 22(6):877–883. doi: 10.1007/s10552-011-9760-5 CrossRefPubMedGoogle Scholar
  17. 17.
    Cheng I, Caberto CP, Lum-Jones A, Seifried A, Wilkens LR, Schumacher FR, Monroe KR, Lim U, Tiirikainen M, Kolonel LN, Henderson BE, Stram DO, Haiman CA, Le Marchand L (2011) Type 2 diabetes risk variants and colorectal cancer risk: the Multiethnic Cohort and PAGE studies. Gut 60(12):1703–1711. doi: 10.1136/gut.2011.237727 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Sainz J, Rudolph A, Hoffmeister M, Frank B, Brenner H, Chang-Claude J, Hemminki K, Forsti A (2012) Effect of type 2 diabetes predisposing genetic variants on colorectal cancer risk. J Clin Endocrinol Metab 97(5):E845–E851. doi: 10.1210/jc.2011-2565 CrossRefPubMedGoogle Scholar
  19. 19.
    Machiela MJ, Lindstrom S, Allen NE, Haiman CA, Albanes D, Barricarte A, Berndt SI, Bueno-de-Mesquita HB, Chanock S, Gaziano JM, Gapstur SM, Giovannucci E, Henderson BE, Jacobs EJ, Kolonel LN, Krogh V, Ma J, Stampfer MJ, Stevens VL, Stram DO, Tjonneland A, Travis R, Willett WC, Hunter DJ, Le Marchand L, Kraft P (2012) Association of type 2 diabetes susceptibility variants with advanced prostate cancer risk in the Breast and Prostate Cancer Cohort Consortium. Am J Epidemiol 176(12):1121–1129. doi: 10.1093/aje/kws191 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Chen F, Wilkens LR, Monroe KR, Stram DO, Kolonel LN, Henderson BE, Le Marchand L, Haiman CA (2011) No association of risk variants for diabetes and obesity with breast cancer: the Multiethnic Cohort and PAGE studies. Cancer Epidemiol Biomarkers Prev 20(5):1039–1042. doi: 10.1158/1055-9965.EPI-11-0135 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Hou N, Zheng Y, Gamazon ER, Ogundiran TO, Adebamowo C, Nathanson KL, Domchek SM, Rebbeck TR, Simon MS, John EM, Hennis A, Nemesure B, Wu SY, Leske MC, Ambs S, Niu Q, Zhang J, Pierce B, Cox NJ, Olopade OI, Huo D (2012) Genetic susceptibility to type 2 diabetes and breast cancer risk in women of European and African ancestry. Cancer Epidemiol Biomarkers Prev 21(3):552–556. doi: 10.1158/1055-9965.EPI-11-0979 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, Schmidt MK, Chang-Claude J, Bojesen SE, Bolla MK, Wang Q, Dicks E, Lee A, Turnbull C, Rahman N, Breast, Ovarian Cancer Susceptibility C, Fletcher O, Peto J, Gibson L, Dos Santos Silva I, Nevanlinna H, Muranen TA, Aittomaki K, Blomqvist C, Czene K, Irwanto A, Liu J, Waisfisz Q, Meijers-Heijboer H, Adank M, Hereditary B, Ovarian Cancer Research Group N, van der Luijt RB, Hein R, Dahmen N, Beckman L, Meindl A, Schmutzler RK, Muller-Myhsok B, Lichtner P, Hopper JL, Southey MC, Makalic E, Schmidt DF, Uitterlinden AG, Hofman A, Hunter DJ, Chanock SJ, Vincent D, Bacot F, Tessier DC, Canisius S, Wessels LF, Haiman CA, Shah M, Luben R, Brown J, Luccarini C, Schoof N, Humphreys K, Li J, Nordestgaard BG, Nielsen SF, Flyger H, Couch FJ, Wang X, Vachon C, Stevens KN, Lambrechts D, Moisse M, Paridaens R, Christiaens MR, Rudolph A, Nickels S, Flesch-Janys D, Johnson N, Aitken Z, Aaltonen K, Heikkinen T, Broeks A, Veer LJ, van der Schoot CE, Guenel P, Truong T, Laurent-Puig P, Menegaux F, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Zamora MP, Perez JI, Pita G, Alonso MR, Cox A, Brock IW, Cross SS, Reed MW, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Henderson BE, Schumacher F, Le Marchand L, Andrulis IL, Knight JA, Glendon G, Mulligan AM, kConFab I, Australian Ovarian Cancer Study G, Lindblom A, Margolin S, Hooning MJ, Hollestelle A, van den Ouweland AM, Jager A, Bui QM, Stone J, Dite GS, Apicella C, Tsimiklis H, Giles GG, Severi G, Baglietto L, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Brenner H, Muller H, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Jones M, Figueroa J, Lissowska J, Brinton L, Goldberg MS, Labreche F, Dumont M, Winqvist R, Pylkas K, Jukkola-Vuorinen A, Grip M, Brauch H, Hamann U, Bruning T, Network G, Radice P, Peterlongo P, Manoukian S, Bonanni B, Devilee P, Tollenaar RA, Seynaeve C, van Asperen CJ, Jakubowska A, Lubinski J, Jaworska K, Durda K, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Bogdanova NV, Antonenkova NN, Dork T, Kristensen VN, Anton-Culver H, Slager S, Toland AE, Edge S, Fostira F, Kang D, Yoo KY, Noh DY, Matsuo K, Ito H, Iwata H, Sueta A, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Shu XO, Lu W, Gao YT, Cai H, Teo SH, Yip CH, Phuah SY, Cornes BK, Hartman M, Miao H, Lim WY, Sng JH, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Shen CY, Hsiung CN, Wu PE, Ding SL, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Blot WJ, Signorello LB, Cai Q, Zheng W, Deming-Halverson S, Shrubsole M, Long J, Simard J, Garcia-Closas M, Pharoah PD, Chenevix-Trench G, Dunning AM, Benitez J, Easton DF (2013) Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genetics 45 (4):353–361, 361e351-352. doi: 10.1038/ng.2563
  23. 23.
    Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, Maranian MJ, Bolla MK, Wang Q, Shah M, Perkins BJ, Czene K, Eriksson M, Darabi H, Brand JS, Bojesen SE, Nordestgaard BG, Flyger H, Nielsen SF, Rahman N, Turnbull C, Bocs, Fletcher O, Peto J, Gibson L, Dos-Santos-Silva I, Chang-Claude J, Flesch-Janys D, Rudolph A, Eilber U, Behrens S, Nevanlinna H, Muranen TA, Aittomaki K, Blomqvist C, Khan S, Aaltonen K, Ahsan H, Kibriya MG, Whittemore AS, John EM, Malone KE, Gammon MD, Santella RM, Ursin G, Makalic E, Schmidt DF, Casey G, Hunter DJ, Gapstur SM, Gaudet MM, Diver WR, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Berg CD, Chanock SJ, Figueroa J, Hoover RN, Lambrechts D, Neven P, Wildiers H, van Limbergen E, Schmidt MK, Broeks A, Verhoef S, Cornelissen S, Couch FJ, Olson JE, Hallberg E, Vachon C, Waisfisz Q, Meijers-Heijboer H, Adank MA, van der Luijt RB, Li J, Liu J, Humphreys K, Kang D, Choi JY, Park SK, Yoo KY, Matsuo K, Ito H, Iwata H, Tajima K, Guenel P, Truong T, Mulot C, Sanchez M, Burwinkel B, Marme F, Surowy H, Sohn C, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Gonzalez-Neira A, Benitez J, Zamora MP, Perez JI, Shu XO, Lu W, Gao YT, Cai H, Cox A, Cross SS, Reed MW, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, kConFab I, Group A, Lindblom A, Margolin S, Teo SH, Yip CH, Taib NA, Tan GH, Hooning MJ, Hollestelle A, Martens JW, Collee JM, Blot W, Signorello LB, Cai Q, Hopper JL, Southey MC, Tsimiklis H, Apicella C, Shen CY, Hsiung CN, Wu PE, Hou MF, Kristensen VN, Nord S, Alnaes GI, Nbcs, Giles GG, Milne RL, McLean C, Canzian F, Trichopoulos D, Peeters P, Lund E, Sund M, Khaw KT, Gunter MJ, Palli D, Mortensen LM, Dossus L, Huerta JM, Meindl A, Schmutzler RK, Sutter C, Yang R, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Hartman M, Miao H, Chia KS, Chan CW, Fasching PA, Hein A, Beckmann MW, Haeberle L, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Ashworth A, Orr N, Schoemaker MJ, Swerdlow AJ, Brinton L, Garcia-Closas M, Zheng W, Halverson SL, Shrubsole M, Long J, Goldberg MS, Labreche F, Dumont M, Winqvist R, Pylkas K, Jukkola-Vuorinen A, Grip M, Brauch H, Hamann U, Bruning T, Network G, Radice P, Peterlongo P, Manoukian S, Bernard L, Bogdanova NV, Dork T, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Devilee P, Tollenaar RA, Seynaeve C, Van Asperen CJ, Jakubowska A, Lubinski J, Jaworska K, Huzarski T, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Slager S, Toland AE, Ambrosone CB, Yannoukakos D, Kabisch M, Torres D, Neuhausen SL, Anton-Culver H, Luccarini C, Baynes C, Ahmed S, Healey CS, Tessier DC, Vincent D, Bacot F, Pita G, Alonso MR, Alvarez N, Herrero D, Simard J, Pharoah PP, Kraft P, Dunning AM, Chenevix-Trench G, Hall P, Easton DF (2015) Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genetics 47 (4):373–380. doi: 10.1038/ng.3242
  24. 24.
    Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR (2012) Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 44(8):955–959. doi: 10.1038/ng.2354 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN, Orr N, Rhie SK, Riboli E, Feigelson HS, Le Marchand L, Buring JE, Eccles D, Miron P, Fasching PA, Brauch H, Chang-Claude J, Carpenter J, Godwin AK, Nevanlinna H, Giles GG, Cox A, Hopper JL, Bolla MK, Wang Q, Dennis J, Dicks E, Howat WJ, Schoof N, Bojesen SE, Lambrechts D, Broeks A, Andrulis IL, Guenel P, Burwinkel B, Sawyer EJ, Hollestelle A, Fletcher O, Winqvist R, Brenner H, Mannermaa A, Hamann U, Meindl A, Lindblom A, Zheng W, Devillee P, Goldberg MS, Lubinski J, Kristensen V, Swerdlow A, Anton-Culver H, Dork T, Muir K, Matsuo K, Wu AH, Radice P, Teo SH, Shu XO, Blot W, Kang D, Hartman M, Sangrajrang S, Shen CY, Southey MC, Park DJ, Hammet F, Stone J, Veer LJ, Rutgers EJ, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Peto J, Schrauder MG, Ekici AB, Beckmann MW, Dos Santos Silva I, Johnson N, Warren H, Tomlinson I, Kerin MJ, Miller N, Marme F, Schneeweiss A, Sohn C, Truong T, Laurent-Puig P, Kerbrat P, Nordestgaard BG, Nielsen SF, Flyger H, Milne RL, Perez JI, Menendez P, Muller H, Arndt V, Stegmaier C, Lichtner P, Lochmann M, Justenhoven C, Ko YD, Gene EI, breast CN, Muranen TA, Aittomaki K, Blomqvist C, Greco D, Heikkinen T, Ito H, Iwata H, Yatabe Y, Antonenkova NN, Margolin S, Kataja V, Kosma VM, Hartikainen JM, Balleine R, kConFab I, Tseng CC, Berg DV, Stram DO, Neven P, Dieudonne AS, Leunen K, Rudolph A, Nickels S, Flesch-Janys D, Peterlongo P, Peissel B, Bernard L, Olson JE, Wang X, Stevens K, Severi G, Baglietto L, McLean C, Coetzee GA, Feng Y, Henderson BE, Schumacher F, Bogdanova NV, Labreche F, Dumont M, Yip CH, Taib NA, Cheng CY, Shrubsole M, Long J, Pylkas K, Jukkola-Vuorinen A, Kauppila S, Knight JA, Glendon G, Mulligan AM, Tollenaar RA, Seynaeve CM, Kriege M, Hooning MJ, van den Ouweland AM, van Deurzen CH, Lu W, Gao YT, Cai H, Balasubramanian SP, Cross SS, Reed MW, Signorello L, Cai Q, Shah M, Miao H, Chan CW, Chia KS, Jakubowska A, Jaworska K, Durda K, Hsiung CN, Wu PE, Yu JC, Ashworth A, Jones M, Tessier DC, Gonzalez-Neira A, Pita G, Alonso MR, Vincent D, Bacot F, Ambrosone CB, Bandera EV, John EM, Chen GK, Hu JJ, Rodriguez-Gil JL, Bernstein L, Press MF, Ziegler RG, Millikan RM, Deming-Halverson SL, Nyante S, Ingles SA, Waisfisz Q, Tsimiklis H, Makalic E, Schmidt D, Bui M, Gibson L, Muller-Myhsok B, Schmutzler RK, Hein R, Dahmen N, Beckmann L, Aaltonen K, Czene K, Irwanto A, Liu J, Turnbull C, Familial Breast Cancer S, Rahman N, Meijers-Heijboer H, Uitterlinden AG, Rivadeneira F, Australian Breast Cancer Tissue Bank I, Olswold C, Slager S, Pilarski R, Ademuyiwa F, Konstantopoulou I, Martin NG, Montgomery GW, Slamon DJ, Rauh C, Lux MP, Jud SM, Bruning T, Weaver J, Sharma P, Pathak H, Tapper W, Gerty S, Durcan L, Trichopoulos D, Tumino R, Peeters PH, Kaaks R, Campa D, Canzian F, Weiderpass E, Johansson M, Khaw KT, Travis R, Clavel-Chapelon F, Kolonel LN, Chen C, Beck A, Hankinson SE, Berg CD, Hoover RN, Lissowska J, Figueroa JD, Chasman DI, Gaudet MM, Diver WR, Willett WC, Hunter DJ, Simard J, Benitez J, Dunning AM, Sherman ME, Chenevix-Trench G, Chanock SJ, Hall P, Pharoah PD, Vachon C, Easton DF, Haiman CA, Kraft P (2013) Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat genetics 45 (4):392–398, 398e391-392. doi: 10.1038/ng.2561
  26. 26.
    Ghoussaini M, Fletcher O, Michailidou K, Turnbull C, Schmidt MK, Dicks E, Dennis J, Wang Q, Humphreys MK, Luccarini C, Baynes C, Conroy D, Maranian M, Ahmed S, Driver K, Johnson N, Orr N, dos Santos Silva I, Waisfisz Q, Meijers-Heijboer H, Uitterlinden AG, Rivadeneira F, Netherlands Collaborative Group on Hereditary B, Ovarian C, Hall P, Czene K, Irwanto A, Liu J, Nevanlinna H, Aittomaki K, Blomqvist C, Meindl A, Schmutzler RK, Muller-Myhsok B, Lichtner P, Chang-Claude J, Hein R, Nickels S, Flesch-Janys D, Tsimiklis H, Makalic E, Schmidt D, Bui M, Hopper JL, Apicella C, Park DJ, Southey M, Hunter DJ, Chanock SJ, Broeks A, Verhoef S, Hogervorst FB, Fasching PA, Lux MP, Beckmann MW, Ekici AB, Sawyer E, Tomlinson I, Kerin M, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Guenel P, Truong T, Cordina-Duverger E, Menegaux F, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Milne RL, Alonso MR, Gonzalez-Neira A, Benitez J, Anton-Culver H, Ziogas A, Bernstein L, Dur CC, Brenner H, Muller H, Arndt V, Stegmaier C, Familial Breast Cancer S, Justenhoven C, Brauch H, Bruning T, Gene Environment Interaction of Breast Cancer in Germany N, Wang-Gohrke S, Eilber U, Dork T, Schurmann P, Bremer M, Hillemanns P, Bogdanova NV, Antonenkova NN, Rogov YI, Karstens JH, Bermisheva M, Prokofieva D, Khusnutdinova E, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Lambrechts D, Yesilyurt BT, Floris G, Leunen K, Manoukian S, Bonanni B, Fortuzzi S, Peterlongo P, Couch FJ, Wang X, Stevens K, Lee A, Giles GG, Baglietto L, Severi G, McLean C, Alnaes GG, Kristensen V, Borrensen-Dale AL, John EM, Miron A, Winqvist R, Pylkas K, Jukkola-Vuorinen A, Kauppila S, Andrulis IL, Glendon G, Mulligan AM, Devilee P, van Asperen CJ, Tollenaar RA, Seynaeve C, Figueroa JD, Garcia-Closas M, Brinton L, Lissowska J, Hooning MJ, Hollestelle A, Oldenburg RA, van den Ouweland AM, Cox A, Reed MW, Shah M, Jakubowska A, Lubinski J, Jaworska K, Durda K, Jones M, Schoemaker M, Ashworth A, Swerdlow A, Beesley J, Chen X, kConFab I, Australian Ovarian Cancer Study G, Muir KR, Lophatananon A, Rattanamongkongul S, Chaiwerawattana A, Kang D, Yoo KY, Noh DY, Shen CY, Yu JC, Wu PE, Hsiung CN, Perkins A, Swann R, Velentzis L, Eccles DM, Tapper WJ, Gerty SM, Graham NJ, Ponder BA, Chenevix-Trench G, Pharoah PD, Lathrop M, Dunning AM, Rahman N, Peto J, Easton DF (2012) Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 44(3):312–318. doi: 10.1038/ng.1049 CrossRefGoogle Scholar
  27. 27.
    Siddiq A, Couch FJ, Chen GK, Lindstrom S, Eccles D, Millikan RC, Michailidou K, Stram DO, Beckmann L, Rhie SK, Ambrosone CB, Aittomaki K, Amiano P, Apicella C, Australian Breast Cancer Tissue Bank I, Baglietto L, Bandera EV, Beckmann MW, Berg CD, Bernstein L, Blomqvist C, Brauch H, Brinton L, Bui QM, Buring JE, Buys SS, Campa D, Carpenter JE, Chasman DI, Chang-Claude J, Chen C, Clavel-Chapelon F, Cox A, Cross SS, Czene K, Deming SL, Diasio RB, Diver WR, Dunning AM, Durcan L, Ekici AB, Fasching PA, Familial Breast Cancer S, Feigelson HS, Fejerman L, Figueroa JD, Fletcher O, Flesch-Janys D, Gaudet MM, Consortium G, Gerty SM, Rodriguez-Gil JL, Giles GG, van Gils CH, Godwin AK, Graham N, Greco D, Hall P, Hankinson SE, Hartmann A, Hein R, Heinz J, Hoover RN, Hopper JL, Hu JJ, Huntsman S, Ingles SA, Irwanto A, Isaacs C, Jacobs KB, John EM, Justenhoven C, Kaaks R, Kolonel LN, Coetzee GA, Lathrop M, Le Marchand L, Lee AM, Lee IM, Lesnick T, Lichtner P, Liu J, Lund E, Makalic E, Martin NG, McLean CA, Meijers-Heijboer H, Meindl A, Miron P, Monroe KR, Montgomery GW, Muller-Myhsok B, Nickels S, Nyante SJ, Olswold C, Overvad K, Palli D, Park DJ, Palmer JR, Pathak H, Peto J, Pharoah P, Rahman N, Rivadeneira F, Schmidt DF, Schmutzler RK, Slager S, Southey MC, Stevens KN, Sinn HP, Press MF, Ross E, Riboli E, Ridker PM, Schumacher FR, Severi G, Dos Santos Silva I, Stone J, Sund M, Tapper WJ, Thun MJ, Travis RC, Turnbull C, Uitterlinden AG, Waisfisz Q, Wang X, Wang Z, Weaver J, Schulz-Wendtland R, Wilkens LR, Van Den Berg D, Zheng W, Ziegler RG, Ziv E, Nevanlinna H, Easton DF, Hunter DJ, Henderson BE, Chanock SJ, Garcia-Closas M, Kraft P, Haiman CA, Vachon CM (2012) A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet 21(24):5373–5384. doi: 10.1093/hmg/dds381 CrossRefGoogle Scholar
  28. 28.
    Ahsan H, Halpern J, Kibriya MG, Pierce BL, Tong L, Gamazon E, McGuire V, Felberg A, Shi J, Jasmine F, Roy S, Brutus R, Argos M, Melkonian S, Chang-Claude J, Andrulis I, Hopper JL, John EM, Malone K, Ursin G, Gammon MD, Thomas DC, Seminara D, Casey G, Knight JA, Southey MC, Giles GG, Santella RM, Lee E, Conti D, Duggan D, Gallinger S, Haile R, Jenkins M, Lindor NM, Newcomb P, Michailidou K, Apicella C, Park DJ, Peto J, Fletcher O, dos Santos Silva I, Lathrop M, Hunter DJ, Chanock SJ, Meindl A, Schmutzler RK, Muller-Myhsok B, Lochmann M, Beckmann L, Hein R, Makalic E, Schmidt DF, Bui QM, Stone J, Flesch-Janys D, Dahmen N, Nevanlinna H, Aittomaki K, Blomqvist C, Hall P, Czene K, Irwanto A, Liu J, Rahman N, Turnbull C, Familial Breast Cancer S, Dunning AM, Pharoah P, Waisfisz Q, Meijers-Heijboer H, Uitterlinden AG, Rivadeneira F, Nicolae D, Easton DF, Cox NJ, Whittemore AS (2014) A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age. Cancer Epidemiol Biomarkers Prev 23(4):658–669. doi: 10.1158/1055-9965.EPI-13-0340 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38(8):904–909. doi: 10.1038/ng1847 CrossRefPubMedGoogle Scholar
  30. 30.
    Wu MC, Kraft P, Epstein MP, Taylor DM, Chanock SJ, Hunter DJ, Lin X (2010) Powerful SNP-set analysis for case-control genome-wide association studies. Am J Hum Genet 86(6):929–942. doi: 10.1016/j.ajhg.2010.05.002 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Team RC (2014) R: A language and environment for statistical computing. R foundation for Statistical computing, ViennaGoogle Scholar
  32. 32.
    Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D (2010) Diabetes and cancer: a consensus report. Diabetes Care 33(7):1674–1685. doi: 10.2337/dc10-0666 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    La Vecchia C, Giordano SH, Hortobagyi GN, Chabner B (2011) Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle. Oncologist 16(6):726–729. doi: 10.1634/theoncologist.2011-0050 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Cai Q, Zhang B, Sung H, Low SK, Kweon SS, Lu W, Shi J, Long J, Wen W, Choi JY, Noh DY, Shen CY, Matsuo K, Teo SH, Kim MK, Khoo US, Iwasaki M, Hartman M, Takahashi A, Ashikawa K, Matsuda K, Shin MH, Park MH, Zheng Y, Xiang YB, Ji BT, Park SK, Wu PE, Hsiung CN, Ito H, Kasuga Y, Kang P, Mariapun S, Ahn SH, Kang HS, Chan KY, Man EP, Iwata H, Tsugane S, Miao H, Liao J, Nakamura Y, Kubo M, Consortium DG-O, Delahanty RJ, Zhang Y, Li B, Li C, Gao YT, Shu XO, Kang D, Zheng W (2014) Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. Nat Genetics 46 (8):886–890. doi: 10.1038/ng.3041
  35. 35.
    Brown AM (2001) Wnt signaling in breast cancer: have we come full circle? Breast Cancer Res 3(6):351–355CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Howe LR, Brown AM (2004) Wnt signaling and breast cancer. Cancer Biol Ther 3(1):36–41CrossRefPubMedGoogle Scholar
  37. 37.
    Fu Z, Deming SL, Fair AM, Shrubsole MJ, Wujcik DM, Shu XO, Kelley M, Zheng W (2011) Well-done meat intake and meat-derived mutagen exposures in relation to breast cancer risk: the Nashville Breast Health Study. Breast Cancer Res Treat 129(3):919–928. doi: 10.1007/s10549-011-1538-7 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Zhiguo Zhao
    • 1
    • 2
  • Wanqing Wen
    • 1
  • Kyriaki Michailidou
    • 3
  • Manjeet K. Bolla
    • 3
  • Qin Wang
    • 3
  • Ben Zhang
    • 1
  • Jirong Long
    • 1
  • Xiao-Ou Shu
    • 1
  • Marjanka K. Schmidt
    • 4
  • Roger L. Milne
    • 5
    • 6
  • Montserrat García-Closas
    • 7
    • 8
  • Jenny Chang-Claude
    • 9
    • 10
  • Sara Lindstrom
    • 11
    • 12
  • Stig E. Bojesen
    • 13
    • 14
    • 15
  • Habibul Ahsan
    • 16
  • Kristiina Aittomäki
    • 17
  • Irene L. Andrulis
    • 18
    • 19
  • Hoda Anton-Culver
    • 20
  • Volker Arndt
    • 21
  • Matthias W. Beckmann
    • 22
  • Alicia Beeghly-Fadiel
    • 1
  • Javier Benitez
    • 23
    • 24
  • Carl Blomqvist
    • 25
  • Natalia V. Bogdanova
    • 26
  • Anne-Lise Børresen-Dale
    • 27
    • 28
  • Judith Brand
    • 29
  • Hiltrud Brauch
    • 30
    • 31
    • 32
  • Hermann Brenner
    • 21
    • 32
    • 33
  • Barbara Burwinkel
    • 34
    • 35
  • Qiuyin Cai
    • 1
  • Graham Casey
    • 36
  • Georgia Chenevix-Trench
    • 37
  • Fergus J. Couch
    • 38
  • Angela Cox
    • 39
  • Simon S. Cross
    • 40
  • Kamila Czene
    • 29
  • Thilo Dörk
    • 41
  • Martine Dumont
    • 42
  • Peter A. Fasching
    • 22
    • 43
  • Jonine Figueroa
    • 44
  • Dieter Flesch-Janys
    • 45
    • 46
  • Olivia Fletcher
    • 8
  • Henrik Flyger
    • 47
  • Florentia Fostira
    • 48
  • Marilie Gammon
    • 49
  • Graham G. Giles
    • 5
    • 6
  • Pascal Guénel
    • 50
    • 51
  • Christopher A. Haiman
    • 36
  • Ute Hamann
    • 52
  • Patricia Harrington
    • 53
  • Mikael Hartman
    • 54
  • Maartje J. Hooning
    • 55
  • John L. Hopper
    • 6
  • Anna Jakubowska
    • 56
  • Farzana Jasmine
    • 16
  • Esther M. John
    • 57
    • 58
  • Nichola Johnson
    • 8
  • Maria Kabisch
    • 52
  • Sofia Khan
    • 59
  • Muhammad Kibriya
    • 16
  • Julia A. Knight
    • 18
    • 60
  • Veli-Matti Kosma
    • 61
    • 62
    • 63
  • Mieke Kriege
    • 55
  • Vessela Kristensen
    • 27
    • 28
    • 64
  • Loic Le Marchand
    • 65
  • Eunjung Lee
    • 36
  • Jingmei Li
    • 29
  • Annika Lindblom
    • 66
  • Artitaya Lophatananon
    • 67
  • Robert Luben
    • 68
  • Jan Lubinski
    • 56
  • Kathleen E. Malone
    • 69
  • Arto Mannermaa
    • 61
    • 62
    • 63
  • Siranoush Manoukian
    • 70
  • Sara Margolin
    • 71
  • Frederik Marme
    • 72
    • 73
  • Catriona McLean
    • 74
  • Hanne Meijers-Heijboer
    • 75
  • Alfons Meindl
    • 76
  • Hui Miao
    • 54
  • Kenneth Muir
    • 67
    • 77
  • Susan L. Neuhausen
    • 78
  • Heli Nevanlinna
    • 59
  • Patrick Neven
    • 79
  • Janet E. Olson
    • 80
  • Barbara Perkins
    • 81
  • Paolo Peterlongo
    • 82
  • Kelly-Anne Phillips
    • 83
    • 84
    • 85
  • Katri Pylkäs
    • 86
  • Anja Rudolph
    • 9
  • Regina Santella
    • 87
    • 88
  • Elinor J. Sawyer
    • 89
  • Rita K. Schmutzler
    • 90
    • 91
    • 92
    • 93
  • Minouk Schoemaker
    • 7
  • Mitul Shah
    • 81
  • Martha Shrubsole
    • 1
  • Melissa C. Southey
    • 94
  • Anthony J. Swerdlow
    • 7
    • 95
  • Amanda E. Toland
    • 96
  • Ian Tomlinson
    • 97
  • Diana Torres
    • 52
  • Thérèse Truong
    • 50
    • 51
  • Giske Ursin
    • 98
    • 104
  • Rob B. Van Der Luijt
    • 99
  • Senno Verhoef
    • 4
  • Shan Wang-Gohrke
    • 10
  • Alice S. Whittemore
    • 58
  • Robert Winqvist
    • 86
    • 100
  • M. Pilar Zamora
    • 101
  • Hui Zhao
    • 102
    • 103
  • Alison M. Dunning
    • 81
  • Jacques Simard
    • 42
  • Per Hall
    • 29
  • Peter Kraft
    • 11
    • 12
  • Paul Pharoah
    • 3
    • 81
  • David Hunter
    • 11
    • 12
  • Douglas F. Easton
    • 3
    • 81
  • Wei Zheng
    • 1
    Email author
  1. 1.Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer CenterVanderbilt University School of MedicineNashvilleUSA
  2. 2.Division of Cancer Biostatistics, Department of BiostatisticsVanderbilt University School of MedicineNashvilleUSA
  3. 3.Department of Public Health and Primary Care, Centre for Cancer Genetic EpidemiologyUniversity of CambridgeCambridgeUK
  4. 4.Netherlands Cancer InstituteAntoni van Leeuwenhoek HospitalAmsterdamThe Netherlands
  5. 5.Cancer Epidemiology CentreCancer Council VictoriaMelbourneAustralia
  6. 6.Centre for Epidemiology and Biostatistics, School of Population and Global HealthThe University of MelbourneMelbourneAustralia
  7. 7.Division of Genetics and EpidemiologyInstitute of Cancer ResearchLondonUK
  8. 8.Division of Cancer Studies, Breakthrough Breast Cancer Research CentreInstitute of Cancer ResearchLondonUK
  9. 9.Division of Cancer EpidemiologyGerman Cancer Research CenterHeidelbergGermany
  10. 10.Department of Obstetrics and GynecologyUniversity of UlmUlmGermany
  11. 11.Program in Genetic Epidemiology and Statistical GeneticsHarvard School of Public HealthBostonUSA
  12. 12.Department of EpidemiologyHarvard School of Public HealthBostonUSA
  13. 13.Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
  14. 14.Department of Clinical Biochemistry, Herlev HospitalCopenhagen University HospitalHerlevDenmark
  15. 15.Copenhagen General Population Study, Herlev HospitalCopenhagen University HospitalHerlevDenmark
  16. 16.Department of Health StudiesThe University of ChicagoChicagoUSA
  17. 17.Department of Clinical Genetics, Helsinki University Central HospitalUniversity of HelsinkiHelsinkiFinland
  18. 18.Prosserman Centre for Health ResearchLunenfeld-Tanenbaum Research Institute of Mount Sinai HospitalTorontoCanada
  19. 19.Department of Molecular GeneticsUniversity of TorontoTorontoCanada
  20. 20.Department of EpidemiologyUniversity of California IrvineIrvineUSA
  21. 21.Division of Clinical Epidemiology and Aging ResearchGerman Cancer Research CenterHeidelbergGermany
  22. 22.Department of Gynaecology and Obstetrics, University Hospital ErlangenFriedrich-Alexander University Erlangen-NurembergErlangenGermany
  23. 23.Human Cancer Genetics ProgramSpanish National Cancer Research CentreMadridSpain
  24. 24.Centro de Investigación en Red de Enfermedades RarasValenciaSpain
  25. 25.Department of Oncology, Helsinki University Central HospitalUniversity of HelsinkiHelsinkiFinland
  26. 26.Department of Radiation OncologyHannover Medical SchoolHannoverGermany
  27. 27.Department of Genetics, Institute for Cancer ResearchRadiumhospitalet, Oslo University HospitalOsloNorway
  28. 28.K.G. Jebsen Center for Breast Cancer Research, Institute of Clinical Medicine, Faculty of MedicineUniversity of OsloOsloNorway
  29. 29.Department of Medical Epidemiology and BiostatisticsKarolinska InstitutetStockholmSweden
  30. 30.Dr. Margarete Fischer-Bosch-Institute of Clinical PharmacologyStuttgartGermany
  31. 31.University of TübingenTübingenGermany
  32. 32.German Cancer ConsortiumGerman Cancer Research CenterHeidelbergGermany
  33. 33.Division of Preventive OncologyGerman Cancer Research CenterHeidelbergGermany
  34. 34.Division of Molecular Genetic EpidemiologyGerman Cancer Research CenterHeidelbergGermany
  35. 35.Molecular Epidemiology GroupGerman Cancer Research CenterHeidelbergGermany
  36. 36.Department of Preventive Medicine, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesUSA
  37. 37.Department of GeneticsQIMR Berghofer Medical Research InstituteBrisbaneAustralia
  38. 38.Department of Laboratory Medicine and PathologyMayo ClinicRochesterUSA
  39. 39.Sheffield Cancer Research, Department of OncologyUniversity of SheffieldSheffieldUK
  40. 40.Academic Unit of Pathology, Department of NeuroscienceUniversity of SheffieldSheffieldUK
  41. 41.Gynaecology Research UnitHannover Medical SchoolHannoverGermany
  42. 42.Centre Hospitalier Universitaire de Québec Research CenterLaval UniversityQuébec CityCanada
  43. 43.Division of Hematology and Oncology, Department of Medicine, David Geffen School of MedicineUniversity of California at Los AngelesLos AngelesUSA
  44. 44.Division of Cancer Epidemiology and GeneticsNational Cancer InstituteRockvilleUSA
  45. 45.Institute for Medical Biometrics and EpidemiologyUniversity Medical Center Hamburg-EppendorfHamburgGermany
  46. 46.Department of Cancer Epidemiology, Clinical Cancer RegistryUniversity Medical Center Hamburg-EppendorfHamburgGermany
  47. 47.Department of Breast Surgery, Herlev HospitalCopenhagen University HospitalHerlevDenmark
  48. 48.Molecular Diagnostics Laboratory, IRRPNational Centre for Scientific Research “Demokritos”AthensGreece
  49. 49.Departments of EpidemiologyUniversity of North Carolina Chapel-HillChapel HillUSA
  50. 50.Inserm (National Institute of Health and Medical Research), CESP (Center for Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of CancerVillejuifFrance
  51. 51.University Paris-Sud, UMRS 1018VillejuifFrance
  52. 52.Molecular Genetics of Breast CancerGerman Cancer Research CenterHeidelbergGermany
  53. 53.Strangeways Research Laboratory, Department of OncologyUniversity of CambridgeCambridgeUK
  54. 54.Saw Swee Hock School of Public HealthNational University of SingaporeSingaporeSingapore
  55. 55.Department of Medical OncologyErasmus University Medical CenterRotterdamThe Netherlands
  56. 56.Department of Genetics and PathologyPomeranian Medical UniversitySzczecinPoland
  57. 57.Cancer Prevention Institute of CaliforniaFremontUSA
  58. 58.Department of Health Research and PolicyStanford University School of MedicineStanfordUSA
  59. 59.Department of Obstetrics and Gynecology, Helsinki University Central HospitalUniversity of HelsinkiHelsinkiFinland
  60. 60.Division of Epidemiology, Dalla Lana School of Public HealthUniversity of TorontoTorontoCanada
  61. 61.Department of Clinical Pathology, Imaging CenterKuopio University HospitalKuopioFinland
  62. 62.Institute of Clinical Medicine, Pathology and Forensic MedicineUniversity of Eastern FinlandKuopioFinland
  63. 63.Cancer Center of Eastern FinlandUniversity of Eastern FinlandKuopioFinland
  64. 64.Department of Clinical Molecular BiologyOslo University Hospital, University of OsloOsloNorway
  65. 65.University of Hawaii Cancer CenterHonoluluUSA
  66. 66.Department of Molecular Medicine and SurgeryKarolinska InstitutetStockholmSweden
  67. 67.Division of Health Sciences, Warwick Medical SchoolWarwick UniversityCoventryUK
  68. 68.Clinical Gerontology, Department of Public Health and Primary CareUniversity of CambridgeCambridgeUK
  69. 69.Division of Public Health SciencesFred Hutchinson Cancer Research CenterSeattleUSA
  70. 70.Unit of Medical Genetics, Department of Preventive and Predictive MedicineFondazione IRCCS Istituto Nazionale dei TumoriMilanItaly
  71. 71.Department of Oncology–PathologyKarolinska InstitutetStockholmSweden
  72. 72.Department of Obstetrics and GynecologyUniversity of HeidelbergHeidelbergGermany
  73. 73.National Center for Tumor DiseasesUniversity of HeidelbergHeidelbergGermany
  74. 74.Anatomical PathologyThe Alfred HospitalMelbourneAustralia
  75. 75.Department of Clinical GeneticsVU University Medical CenterAmsterdamThe Netherlands
  76. 76.Division of Gynaecology and ObstetricsTechnische Universität MünchenMunichGermany
  77. 77.Institute of Population HealthUniversity of ManchesterManchesterUK
  78. 78.Beckman Research Institute of City of HopeDuarteUSA
  79. 79.Department of Oncology, Multidisciplinary Breast Centre and Gynaecological OncologyKU Leuven - University of Leuven, University Hospitals LeuvenLouvainBelgium
  80. 80.Department of Health Sciences ResearchMayo ClinicRochesterUSA
  81. 81.Department of Oncology, Centre for Cancer Genetic EpidemiologyUniversity of CambridgeCambridgeUK
  82. 82.IFOM, Fondazione Istituto FIRC di Oncologia MolecolareMilanItaly
  83. 83.Peter MacCallum Cancer CenterThe University of MelbourneMelbourneAustralia
  84. 84.Sir Peter MacCallum Department of OncologyThe University of MelbourneMelbourneAustralia
  85. 85.Department of Medicine, St Vincent’s HospitalThe University of MelbourneFitzroyAustralia
  86. 86.Laboratory of Cancer Genetics and Tumor Biology, Department of Clinical Chemistry and Biocenter OuluUniversity of OuluOuluFinland
  87. 87.Herbert Irving Comprehensive Cancer CenterColumbia University Medical CenterNew YorkUSA
  88. 88.Department of Environmental Health SciencesMailman School of Public Health of Columbia UniversityNew YorkUSA
  89. 89.Research OncologyGuy’s Hospital, King’s College LondonLondonUK
  90. 90.Division of Molecular Gyneco-Oncology, Department of Gynaecology and ObstetricsUniversity Hospital of CologneCologneGermany
  91. 91.Center for Integrated OncologyUniversity Hospital of CologneCologneGermany
  92. 92.Center for Molecular MedicineUniversity Hospital of CologneCologneGermany
  93. 93.Center of Familial Breast and Ovarian CancerUniversity Hospital of CologneCologneGermany
  94. 94.Department of PathologyThe University of MelbourneMelbourneAustralia
  95. 95.Division of Breast Cancer ResearchInstitute of Cancer ResearchLondonUK
  96. 96.Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer CenterThe Ohio State UniversityColumbusUSA
  97. 97.Wellcome Trust Centre for Human Genetics and Oxford Biomedical Research CentreUniversity of OxfordOxfordUK
  98. 98.Cancer Registry of NorwayOsloNorway
  99. 99.Department of Medical GeneticsUniversity Medical Center UtrechtUtrechtThe Netherlands
  100. 100.Laboratory of Cancer Genetics and Tumor BiologyNorthern Finland Laboratory Centre NordLabOuluFinland
  101. 101.Servicio de Oncología MédicaHospital Universitario La PazMadridSpain
  102. 102.Vesalius Research CenterLouvainBelgium
  103. 103.Laboratory for Translational Genetics, Department of OncologyUniversity of LeuvenLouvainBelgium
  104. 104.Department of Nutrition, Institute of Basic Medical SciencesUniversity of OsloOsloNorway

Personalised recommendations